



Figure S4: Overexpression of wild-type KRAS drives resistance to RAF/EGFR and RAF/MEK inhibitor combinations. (A, B) VACO432 cells overexpressing wild-type KRAS (KRAS WT) or YFP control were treated with the indicated concentrations of drugs for 3d and relative cell titer was determined. RAF/EGFR inhibitor combinations are shown in (A), and RAF/MEK inhibitor combination is shown in (B). Encorafenib (ENC), cetuximab (CET), dabrafenib (DAB), panitumumab (PAN), vemurafenib (VEM), selumetinib (SEL). (C) VACO432 cells overexpressing KRAS WT or YFP control were treated with the indicated concentrations of drugs for 24h and western blotting was performed with the indicated antibodies.